| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(10)62318-5 |
| P698 | PubMed publication ID | 21334736 |
| P50 | author | Ute Eisenberger | Q46656867 |
| Petra Reinke | Q62091040 | ||
| P2093 | author name string | Wolfgang Fischer | |
| Thomas Becker | |||
| Klemens Budde | |||
| Stefan Kramer | |||
| Claudia Sommerer | |||
| Wolfgang Arns | |||
| ZEUS Study Investigators | |||
| Frank Pietruck | |||
| Harald Gschaidmeier | |||
| P2860 | cites work | A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group | Q29614889 |
| Prediction of creatinine clearance from serum creatinine | Q29615603 | ||
| Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data | Q31004418 | ||
| Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study | Q33349178 | ||
| Benefit-risk assessment of sirolimus in renal transplantation | Q33364817 | ||
| Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials | Q33371189 | ||
| Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies | Q34546358 | ||
| Calcineurin inhibitor nephrotoxicity | Q34945314 | ||
| Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors | Q36119726 | ||
| Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients | Q36677625 | ||
| Calcineurin inhibitor-free immunosuppression in kidney transplantation | Q36889001 | ||
| mToR inhibitors-induced proteinuria: mechanisms, significance, and management | Q37218125 | ||
| Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors | Q37454285 | ||
| Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients | Q42626947 | ||
| Low toxicity regimens in renal transplantation: a country subset analysis of the Symphony study | Q43248194 | ||
| Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation. | Q43272834 | ||
| The natural history of chronic allograft nephropathy | Q44688416 | ||
| Surrogate markers for long-term renal allograft survival | Q44935481 | ||
| Protocol conversion from a calcineurin inhibitor based therapy to sirolimus | Q46041703 | ||
| Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial | Q46155747 | ||
| Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus | Q46208453 | ||
| Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. | Q46492984 | ||
| Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients | Q46702760 | ||
| Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. | Q46702764 | ||
| Reduced exposure to calcineurin inhibitors in renal transplantation | Q46840533 | ||
| Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus | Q46936585 | ||
| Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab. | Q52926796 | ||
| Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6-Month Course of Steroids | Q56908156 | ||
| 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients | Q79444349 | ||
| One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients | Q79541929 | ||
| Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation | Q80102211 | ||
| Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology | Q80783273 | ||
| P433 | issue | 9768 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 837-847 | |
| P577 | publication date | 2011-02-19 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial | |
| P478 | volume | 377 |
| Q41661712 | A Prospective Randomised Paired Trial of Sirolimus versus Tacrolimus as Primary Immunosuppression following Non-Heart Beating Donor Kidney Transplantation |
| Q39024541 | A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation |
| Q38041260 | A drug safety evaluation of everolimus in kidney transplantation |
| Q88161774 | A pharmacological rationale for improved everolimus dosing in oncology and transplant patients |
| Q34805919 | A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients |
| Q56035477 | A review on therapeutic drug monitoring of the mTOR class of immunosuppressants: everolimus and sirolimus |
| Q27000107 | A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients |
| Q36386694 | Activation of the Mammalian Target of Rapamycin in the Rostral Ventromedial Medulla Contributes to the Maintenance of Nerve Injury-Induced Neuropathic Pain in Rat |
| Q30383901 | Adenosine Monophosphate-activated Protein Kinase (AMPK) Activators For the Prevention, Treatment and Potential Reversal of Pathological Pain. |
| Q35776408 | Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years |
| Q38068519 | Adverse events associated with mTOR inhibitors |
| Q87474277 | Alemtuzumab induction therapy in kidney transplantation |
| Q40220124 | An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade |
| Q34753440 | Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients |
| Q34638056 | Belatacept : a new biological agent for maintenance immunosuppression in kidney transplantation |
| Q41766468 | Belatacept conversion in African American kidney transplant recipients with severe renal dysfunction |
| Q82978400 | Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment |
| Q38779769 | Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis. |
| Q38220750 | Calcineurin inhibitor avoidance and withdrawal for kidney transplantation: a systematic review and meta-analysis of randomized controlled trials |
| Q38668601 | Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients. |
| Q36908763 | Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol |
| Q47309233 | Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial |
| Q38177489 | Cardiovascular complications after transplantation: treatment options in solid organ recipients |
| Q30301338 | Cellular and molecular immune profiles in renal transplant recipients after conversion from tacrolimus to sirolimus |
| Q35048950 | Cellular effects of everolimus and sirolimus on podocytes |
| Q38035660 | Chronic renal allograft injury: early detection, accurate diagnosis and management. |
| Q37929851 | Clinical application of mTORi based immunosuppression for renal transplantation in India |
| Q38382365 | Clinical management of the uraemic syndrome in chronic kidney disease |
| Q41701385 | Contrast-enhanced ultrasonography in the early period after kidney transplantation predicts long-term allograft function. |
| Q38241710 | Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients |
| Q52888129 | Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study. |
| Q54453612 | Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study. |
| Q43673379 | Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis |
| Q38190678 | Conversion to mTOR-inhibitor-based immunosuppression: which patients and when? |
| Q51744862 | Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies. |
| Q26992343 | Corticosteroid and calcineurin inhibitor sparing regimens in kidney transplantation |
| Q43529813 | Cost-effectiveness of modern mTOR inhibitor based immunosuppression compared to the standard of care after renal transplantation in Germany |
| Q38096463 | Current pharmacotherapeutical options for the prevention of kidney transplant rejection |
| Q26829789 | Current state of renal transplant immunosuppression: Present and future |
| Q82591479 | De novo use of everolimus with elimination or minimization of cyclosporine in renal transplant recipients |
| Q35022430 | Deferred pre-emptive switch from calcineurin inhibitor to sirolimus leads to improvement in GFR and expansion of T regulatory cell population: a randomized, controlled trial |
| Q54960188 | Deletion of Tsc2 in Nociceptors Reduces Target Innervation, Ion Channel Expression, and Sensitivity to Heat. |
| Q56970934 | Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant p |
| Q48185108 | Donor Specificity but Not Broadness of Sensitization Is Associated With Antibody-Mediated Rejection and Graft Loss in Renal Allograft Recipients. |
| Q50997883 | Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus. |
| Q52889823 | Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. |
| Q47812723 | Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial |
| Q54530926 | Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation. |
| Q38731333 | Effect of Immunosuppressive Drugs on Humoral Allosensitization after Kidney Transplant. |
| Q40655904 | Effectiveness of the Combination of Everolimus and Tacrolimus With High Dosage of Mizoribine for Living Donor-Related Kidney Transplantation |
| Q36255504 | Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials |
| Q54334382 | Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study. |
| Q87491684 | Efficacy and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in kidney transplant recipients |
| Q53599480 | Efficacy of everolimus with reduced-exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial. |
| Q38032010 | Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing. |
| Q39118320 | Everolimus and Advagraf Ab Initio in Combined Liver and Kidney Transplant With Donor-Specific Antibodies: A Case Report |
| Q28067598 | Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update |
| Q37337337 | Everolimus for subependymal giant cell astrocytoma: 5-year final analysis |
| Q38646743 | Everolimus immunosuppression in kidney transplantation: What is the optimal strategy? |
| Q33396703 | Everolimus in clinical practice in long-term liver transplantation: an observational study |
| Q90178790 | Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR) |
| Q26783981 | Everolimus in de novo liver transplant recipients: a systematic review |
| Q40176051 | Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial |
| Q38406581 | Everolimus-Induced Systemic Serositis After Simultaneous Liver and Kidney Transplantation: A Case Report |
| Q91768973 | Everolimus-based Immunosuppression Possibly Suppresses Mean Fluorescence Intensity Values of De Novo Donor-specific Antibodies After Primary Kidney Transplantation |
| Q38229930 | Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis |
| Q37992135 | Everolimus: preventing organ rejection in adult kidney transplant recipients |
| Q53633264 | Evolution of allograft fibrosis and function in kidney transplant recipients: a retrospective analysis of stable patients under CNI and mTORi. |
| Q34417150 | Experience of using everolimus in the early stage of living donor liver transplantation |
| Q40513558 | Experience with belatacept rescue therapy in kidney transplant recipients. |
| Q40856064 | Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid. |
| Q53570157 | Fibrosis progression according to epithelial-mesenchymal transition profile: a randomized trial of everolimus versus CsA. |
| Q41673673 | Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study |
| Q47928939 | Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the SPIESSER study |
| Q40325057 | Glomerular Diseases and Renal Transplantation: Pathogenic Pathways and Evolution of Therapeutic Interventions |
| Q54249303 | Halting renal fibrosis: an unexpected role for mTORC2 signaling. |
| Q55515813 | Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study. |
| Q58796793 | Hyaluronic Acid-Decorated Chitosan Nanoparticles for CD44-Targeted Delivery of Everolimus |
| Q38498420 | Hypomagnesaemia in kidney transplantation |
| Q38429887 | Identifying endpoints to predict the influence of immunosuppression on long-term kidney graft survival |
| Q38391150 | Immunological risks of minimization strategies |
| Q50944577 | Immunosuppression Modification by Everolimus With Minimization of Calcineurin Inhibitors Recovers Kidney Graft Function Even in Patients With Very Late Conversion and Also With Poor Graft Function. |
| Q83445908 | Immunosuppression without calcineurin inhibition: by ZEUS |
| Q38470256 | Immunosuppressive minimization with mTOR inhibitors and belatacept. |
| Q54411021 | Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen. |
| Q28069954 | Improving the outcome of kidney transplantation by ameliorating renal ischemia reperfusion injury: lost in translation? |
| Q48140331 | In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity. |
| Q51037981 | Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen. |
| Q50848721 | Induction Immunosuppressive Therapy With Everolimus and Low-Dose Tacrolimus Extended-Release Preserves Good Renal Function at 1 Year After Kidney Transplantation. |
| Q35953320 | Infectious risks and optimal strength of maintenance immunosuppressants in rituximab-treated kidney transplantation |
| Q51161846 | Influence of conversion from calcineurin inhibitors to everolimus on fibrosis, inflammation, tubular damage and vascular function in renal transplant patients. |
| Q41812610 | Inhibition of MTOR disrupts autophagic flux in podocytes |
| Q48416038 | Inhibition of calcineurin in the prefrontal cortex induced depressive-like behavior through mTOR signaling pathway |
| Q37184425 | Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation |
| Q41313340 | Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients? A Systemic Review of Medium-term Outcomes |
| Q64103860 | Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study |
| Q26746936 | Metabolic consequences of modern immunosuppressive agents in solid organ transplantation |
| Q36087779 | Minimization vs tailoring: Where do we stand with personalized immunosuppression during renal transplantation in 2015? |
| Q34023028 | More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients |
| Q38102315 | New perspectives of immunosuppression. |
| Q58719130 | Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials |
| Q42418219 | Open-Label, Randomized Study of Transition From Tacrolimus to Sirolimus Immunosuppression in Renal Allograft Recipients. |
| Q41928074 | Optimising the use of mTOR inhibitors in renal transplantation |
| Q42478371 | Oscillatory mTOR inhibition and Treg increase in kidney transplantation. |
| Q37464878 | Outcomes in ethnic minority renal transplant recipients receiving everolimus versus mycophenolate: comparative risk assessment results from a pooled analysis |
| Q45117076 | Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients |
| Q84208187 | Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients |
| Q38863078 | Practical considerations for the use of mTOR inhibitors. |
| Q54361889 | Predictive factors of allosensitization in renal transplant patients switched from calcineurin to mTOR inhibitors. |
| Q27315815 | Protective effects of the mTOR inhibitor everolimus on cytoskeletal injury in human podocytes are mediated by RhoA signaling |
| Q53145957 | Rapamycin Interferes With Postdepletion Regulatory T Cell Homeostasis and Enhances DSA Formation Corrected by CTLA4-Ig. |
| Q30409683 | Rapamycin blocks fibrocyte migration and attenuates bronchiolitis obliterans in a murine model |
| Q47368760 | Rapamycin exacerbates cardiovascular dysfunction after complete high-thoracic spinal cord injury |
| Q53551249 | Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. |
| Q42343473 | Renal association clinical practice guideline in post-operative care in the kidney transplant recipient |
| Q42679895 | Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation. |
| Q52874072 | Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial. |
| Q38127967 | Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation |
| Q55266341 | Risk factors associated with post–kidney transplant malignancies: an article from the Cancer-Kidney International Network. |
| Q38242068 | Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis |
| Q37935772 | Role of everolimus in pancreatic neuroendocrine tumors |
| Q38947867 | Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients. |
| Q38914374 | Roles of mTOR complexes in the kidney: implications for renal disease and transplantation. |
| Q38669190 | Safety of mTOR inhibitors in adult solid organ transplantation. |
| Q30411470 | Short-course rapamycin treatment preserves airway epithelium and protects against bronchiolitis obliterans |
| Q55452264 | Successful treatment of recurrent immunoglobulin a nephropathy using steroid pulse therapy plus tonsillectomy 10 years after kidney transplantation: a case presentation. |
| Q38866153 | Sulodexide alone or in combination with low doses of everolimus inhibits the hypoxia-mediated epithelial to mesenchymal transition in human renal proximal tubular cells. |
| Q48329048 | Switch to an everolimus-facilitated cyclosporine A sparing immunosuppression improves glycemic control in selected kidney transplant recipients. |
| Q33617408 | Systemic meta-analysis assessing the short term applicability of early conversion to mammalian target of rapamycin inhibitors in kidney transplant |
| Q24187866 | Target of rapamycin inhibitors (TORi) as maintenance immunosuppression for kidney transplant recipients |
| Q24201591 | Target of rapamycin inhibitors (TORi) as maintenance immunosuppression for kidney transplant recipients |
| Q38998418 | Targeting AMPK for the Alleviation of Pathological Pain |
| Q34995106 | The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial. |
| Q36644337 | The Peripheral NK Cell Repertoire after Kidney Transplantation is Modulated by Different Immunosuppressive Drugs |
| Q44658058 | The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes |
| Q50569364 | The effect of sirolimus-based immunosuppression vs. conventional prophylaxis therapy on cytomegalovirus infection after liver transplantation. |
| Q45991438 | The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study. |
| Q37937222 | The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen. |
| Q34303766 | The mTOR-inhibitor rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response |
| Q33412367 | The pros and the cons of mTOR inhibitors in kidney transplantation |
| Q26864686 | The use of novel diagnostics to individualize immunosuppression following transplantation |
| Q90230633 | Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges |
| Q40073566 | Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens |
| Q83987089 | Transplantation: Early switch from calcineurin inhibitors to mTOR inhibitors leads to improved renal graft function |
| Q53669745 | Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis. |
| Q24635082 | Urban legends: recurrent aphthous stomatitis |
| Q26991858 | Urinary tract infection in renal transplantation |
| Q30871481 | Use of everolimus in renal transplant recipients: data from a national registry |
| Q40168658 | Variances in the Use of Everolimus in Kidney Transplantation: A 2-Year Registry of Everyday Practice |
| Q51595119 | Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus. |
| Q87274914 | [Modern immunosuppression after solid organ transplantation] |
| Q93208179 | mTOR Inhibitor Everolimus in Regulatory T Cell Expansion for Clinical Application in Transplantation |
| Q46764150 | mTOR inhibition with temsirolimus causes acute increases in glomerular permeability, but inhibits the dynamic permeability actions of puromycin aminonucleoside |
| Q37964271 | mTOR inhibitor-associated proteinuria in kidney transplant recipients |
| Q38250176 | mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern? |
| Q38962103 | mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions |
| Q34340709 | mTORC1 inhibition induces pain via IRS-1-dependent feedback activation of ERK. |
Search more.